Feedback

Browsing by P


Use an asterisk (*) for partial word searches (e.g. pemph*)

245 results found.

1.
2.
Ordering Recommendation:   Use to diagnose oligodendrogliomas and predict response to therapy.
3.
Ordering Recommendation:   ()Assess and monitor patient with possible IgA pemphigus, a RARE disease with certain clinical and histopathological subtypes.()If other types of pemphigus are of diagnostic consideration, order the panel test for pemphigus antibodies (0090650) first or concurrently with this test.
4.
5.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
6.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
7.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
8.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
9.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
10.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
11.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
12.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
13.
14.
15.
16.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
17.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
18.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
19.
20.
Ordering Recommendation:   Screen for exocrine pancreatic insufficiency.
21.
Ordering Recommendation:   Aids in the diagnosis and monitoring of pancreatic neuroendocrine tumors.
22.
Ordering Recommendation:   For adults with idiopathic pancreatitis if other components of panel (CTFR, PRSS1, and SPINK1) have been sequenced without providing a complete explanation for the pancreatitis.
23.
Ordering Recommendation:   Preferred test for individuals who are <20 years of age OR those with two affected first-degree relatives.
24.
Ordering Recommendation:   For adults with idiopathic pancreatitis if other components of panel (CFTR, CTRC, and PRSS1 sequencing) have been sequenced without providing a complete explanation for the pancreatitis.
25.
Ordering Recommendation:   Preferred test for individual with history of idiopathic pancreatitis.
26.
27.
28.
29.
Ordering Recommendation:   Aid in the diagnosis of paraneoplastic neurologic syndromes associated with malignancy. Order based on clinical presentation. PCCA/ANNA antibodies are screened by IFA; if IFA screen is positive, a specific titer (PCCA or ANNA) and immunoblot will be added.
30.
Ordering Recommendation:   Aid in the diagnosis of paraneoplastic neurologic syndromes associated with malignancy for CSF specimens only. Order based on clinical presentation. PCCA/ANNA antibodies are screened by IFA; if IFA screen is positive, a specific titer (PCCA or ANNA) and immunoblot will be added.
31.
Ordering Recommendation:   ()Assess patient with possible paraneoplastic pemphigus (PNP), a RARE paraneoplastic disease associated with lymphoproliferative disorders/malignancies and severe pemphigus clinical features with characteristic IgG antibodies to rodent substrates.()If other, more common, types of pemphigus are of diagnostic consideration, order the antibody panel test for pemphigus (0090650) first or concurrently with this test.()If IgA paraneoplastic antibody testing is required, request through ARUP Client Services 800-242-2787 option 2.
32.
33.
Ordering Recommendation:   Screen for and detect blood parasites, including species of Plasmodium, Babesia, microfilaria, and trypanosomes. Travel history required. Use to detect blood spirochetes.
34.
Ordering Recommendation:   Test for persistent diarrhea (>14 days) or known risk factors if Cryptosporidium, Cyclospora or Cystoisospora is the suspected infectious agent.
35.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
36.
37.
Ordering Recommendation:   Aid in the differentiation of parathyroid tissue from thyroid tissue.
38.
39.
Ordering Recommendation:   Use to evaluate calcium dysregulation.
40.
Ordering Recommendation:   Aid in the evaluation of unexplained hypercalcemia, particularly in suspected hypercalcemia of malignancy.
41.
42.
43.
Ordering Recommendation:   Preferred test for initial diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) and quantification of PNH clones.
44.
Ordering Recommendation:   Use to monitor subclinical paroxysmal nocturnal hemoglobinuria and eculizumab treatment. Preferred initial diagnostic test is Paroxysmal Nocturnal Hemoglobinuria (PNH), RBC and WBC (2005006).
45.
Ordering Recommendation:   Use to quantify or monitor paroxysmal nocturnal hemoglobinuria clone size. Preferred initial diagnostic test is Paroxysmal Nocturnal Hemoglobinuria (PNH), RBC and WBC (2005006).
46.
47.
48.
49.
50.
51.
Ordering Recommendation:   Diagnose and monitor human parvovirus infection in patient with suppressed or delayed immune response.
52.
53.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
54.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
55.
56.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
57.
Ordering Recommendation:   Do not use for initial prostate cancer screening. Preferred test is total prostate specific antigen (PSA) (0070121) in conjunction with digital rectal exam. The PCA3 test may be useful, in conjunction with other patient information, to aid in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies and for whom a repeat biopsy would be recommended by a urologist based on current standard of care.
58.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
59.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
60.
Ordering Recommendation:   Screening test for monoclonal antibody therapy.
61.
Ordering Recommendation:   ()This is the preferred antibody panel for initial diagnostic assessment and disease monitoring in pemphigoid, epidermolysis bullosa acquisita, and linear IgA bullous dermatosis. Bullous pemphigoid and other pemphigoid variants, epidermolysis bullosa acquisita, and linear IgA bullous dermatosis present with blistering, erosions, pruritus, and urticaria, which affect skin and mucous membranes.()Panel components include IgG and IgA epithelial BMZ antibodies and IgG bullous pemphigoid BP 180 & 230 antigens. To order individual component tests, refer to antibody testing for IgG BMZ (0092056), IgA BMZ (0092057), and/or IgG bullous pemphigoid BP 180 & 230 antigens (0092566).()To screen for pemphigoid along with other possible immunobullous diseases, order concurrently with the pemphigus antibody panel (0090650), IgG collagen type VII antibody (2010905), AND perilesional skin biopsy for direct immunofluorescence (0092572).
62.
Ordering Recommendation:   ()This is the preferred panel for initial assessment and disease monitoring in IgG-variant pemphigus. Pemphigus vulgaris and pemphigus foliaceus are the most common types of pemphigus with blistering and erosive disease affecting skin and mucous membranes.()Panel components include antibody testing for IgG epithelial cell surface and IgG desmoglein 1 and 3. To order individual component tests, refer to (0090299) and/or (0090649).()To screen for pemphigus along with other possible immunobullous diseases, order concurrently with antibody panel test for pemphigoid (0092001), IgG collagen type VII antibody (2010905), AND perilesional skin biopsy for direct immunofluorescence (0092572).
63.
64.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
65.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
66.
Ordering Recommendation:   Most comprehensive test to identify causative periodic fever syndromes mutations.
67.
Ordering Recommendation:   Acceptable molecular test for periodic fever syndromes but does not detect deletions or duplications.
68.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
69.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
70.
Ordering Recommendation:   Diagnostic confirmation in symptomatic individual; disease prediction in presymptomatic individual with family history of Peutz-Jeghers syndrome (PJS).
71.
Ordering Recommendation:   Preferred test for confirming diagnosis in symptomatic individual; disease prediction in presymptomatic individual with family history of Peutz-Jeghers syndrome (PJS).
72.
73.
74.
75.
76.
77.
Ordering Recommendation:   Detect exposure.
78.
79.
80.
81.
82.
83.
84.
85.
86.
Ordering Recommendation:   Use for monitoring patients with an established diagnosis of phenylketonuria (PKU).
87.
Ordering Recommendation:   Use for monitoring patients with an established diagnosis of phenylketonuria (PKU).
88.
89.
90.
91.
Ordering Recommendation:   Therapeutic drug management for patients with renal failure or conditions that may alter albumin concentrations.
92.
Ordering Recommendation:   Preferred test for therapeutic drug management in patients with renal failure or conditions that may alter albumin concentrations.
93.
94.
Ordering Recommendation:   Not a recommended panel for the definitive diagnosis of antiphospholipid syndrome (APS).
95.
Ordering Recommendation:   Biomarker associated with ethanol consumption; may be helpful in monitoring alcohol abstinence.
96.
97.
98.
99.
Ordering Recommendation:   May be useful as an independent risk marker for thrombosis associated with APS and related diseases. Consider using when all criteria aPL antibody tests are negative; positive results should be reported to document persistence.
100.
Ordering Recommendation:   May be useful as an independent risk marker for thrombosis associated with APS and related diseases. Consider using when all criteria aPL antibody tests are negative; positive results should be reported to document persistence.
101.
Ordering Recommendation:   Preferred second-line test for strong suspicion of seronegative antiphospholipid syndrome. Order incrementally or concurrently with other noncriteria antiphospholipid antibody tests.
102.
Ordering Recommendation:   Not a recommended panel for the diagnosis of antiphospholipid syndrome (APS). The combined IgG and IgM Phosphatidylserine test is the preferred second-line testing in seronegative APS.
103.
Ordering Recommendation:   Aids in the differential diagnosis of membranous glomerulonephritis (MGN) or nephrotic syndrome of unknown etiology.
104.
105.
106.
107.
Ordering Recommendation:   () Predicts response to anti-EGFR and AKT/mTOR pathway therapies in a variety of malignancies (eg, colorectal, ovarian, and breast cancer).() Detects activating PIK3CA mutations in exons 9 and 20.
108.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
109.
110.
111.
112.
113.
114.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
115.
Ordering Recommendation:   Assay detects elevated PAI concentrations, low concentrations may not be accurately quantified. Not a first-line test for diagnosing inherited thrombotic or bleeding disorders.
116.
Ordering Recommendation:   Assess genetic risk for thrombosis.
117.
118.
119.
Ordering Recommendation:   Not recommended for the diagnosis of immune thrombocytopenic purpura (ITP). Use to detect platelet-specific antibodies in suspected fetal or neonatal alloimmune thrombocytopenia, posttransfusion purpura, or multiplatelet transfusion refractoriness. Preferred test is Platelet Antibodies, Indirect with Reflex to Identification (0051718).
120.
Ordering Recommendation:   Not recommended for the diagnosis of immune thrombocytopenic purpura (ITP). Preferred test for platelet-specific antibodies in suspected fetal or neonatal alloimmune thrombocytopenia, posttransfusion purpura, or multiplatelet transfusion refractoriness.
121.
122.
Ordering Recommendation:   Assess risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT). Test may be ordered for parental or fetal genotyping.
123.
Ordering Recommendation:   Assess risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT). Test may be ordered for parental or fetal genotyping.
124.
Ordering Recommendation:   Assess risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT). Test may be ordered for parental or fetal genotyping.
125.
Ordering Recommendation:   Assess risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT).Test may be ordered for parental or fetal genotyping.
126.
Ordering Recommendation:   Assess risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT). Test may be ordered for parental or fetal genotyping.
127.
Ordering Recommendation:   Assess risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT). Test may be ordered for parental or fetal genotyping.
128.
Ordering Recommendation:   Assess risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT). Test may be ordered for parental or fetal genotyping.
129.
Ordering Recommendation:   Use in risk assessment for fetal and neonatal alloimmune thrombocytopenia (FNAIT). Test may be ordered for parental or fetal genotyping.
130.
131.
132.
133.
Ordering Recommendation:   Rapid confirmatory diagnostic test for APL.
134.
Ordering Recommendation:   Provides genetic confirmation of APL. Predict relapse risk and monitor for minimal residual disease post-consolidation therapy.
135.
136.
137.
138.
139.
140.
141.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
142.
Ordering Recommendation:   Molecular confirmation of a suspected clinical diagnosis of autosomal dominant polycystic kidney disease (ADPKD).
143.
Ordering Recommendation:   Preferred test for molecular confirmation of a suspected clinical diagnosis of autosomal dominant polycystic kidney disease (ADPKD).
144.
Ordering Recommendation:   Useful in family studies to determine risk for acute intermittent porphyria (AIP).
145.
Ordering Recommendation:   Essential first-line test for suspected acute porphyria in adults. Use in determining metabolic response to IV hematin.
146.
Ordering Recommendation:   Evaluate patients with suspected porphyria presenting with neurologic/psychiatric, abdominal, and/or cutaneous symptoms.
147.
Ordering Recommendation:   Distinguish among acute intermittent porphyria (AIP) , variegate porphyria (VP), and hereditary coproporphyria (HCP).
148.
Ordering Recommendation:   Evaluate cutaneous photosensitivity to exclude or include porphyria cutanea tarda (PCT).
149.
150.
Ordering Recommendation:   Monitor porphyria cutanea tarda (PCT). Confirm diagnosis of suspected variegate porphyria (VP), erythropoietic protoporphyria (EPP).
151.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
152.
153.
154.
155.
156.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
157.
158.
159.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
160.
Ordering Recommendation:   Compliance monitoring for pain management.
161.
162.
Ordering Recommendation:   Evaluate the cause of an isolated prolonged PTT in a patient who is not currently bleeding.
163.
Ordering Recommendation:   Preconception and prenatal carrier screening. Refer to "Additional Technical Information" document for mutations tested.
164.
Ordering Recommendation:   Preconception and prenatal carrier screening. Refer to "Additional Technical Information" document for mutations tested.
165.
Ordering Recommendation:   Preconception and prenatal carrier screening. Refer to "Additional Technical Information" document for mutations tested.
166.
167.
Ordering Recommendation:   Preferred genetic test for individual with clinical phenotype of primary antibody deficiency (eg, common variable immunodeficiency). For hyper IgM syndrome genetic testing, refer to hyper IgM syndrome sequencing and deletion/duplication panel (2011154). For agammaglobulinemia genetic testing, refer to agammaglobulinemia sequencing and deletion/duplication panel (2011151).
168.
Ordering Recommendation:   Molecular (DNA) test to confirm a diagnosis of primary carnitine deficiency when Primary Carnitine Deficiency (SLC22A5) Sequencing (0051682) does not identify two causative mutations. Carrier testing for individuals with a family history of a deletion or duplication in the SLC22A5 gene.
169.
Ordering Recommendation:   Molecular (DNA) test to confirm a diagnosis of primary carnitine deficiency following clinical and/or biochemical presentation. To diagnose or rule out primary carnitine deficiency, refer to Carnitine, Free & Total (Includes Carnitine, Esterified) (0080068).
170.
Ordering Recommendation:   Preferred molecular (DNA) test to confirm a diagnosis of primary carnitine deficiency following clinical and/or biochemical presentation. To diagnose or rule out primary carnitine deficiency, refer to Carnitine, Free & Total (Includes Carnitine, Esterified) (0080068) and Carnitine, Free and Total, Urine (0081308).
171.
172.
Ordering Recommendation:   Aids in diagnosis, prognosis, and management of acute and chronic heart failure.
173.
174.
175.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
176.
177.
178.
Ordering Recommendation:   Aids in the workup of suspected infertility, detection of ovulation, and assessment of the luteal phase.
179.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
180.
Ordering Recommendation:   Refer to Additional Technical Information document.
181.
Ordering Recommendation:   Aids in the detection of insulinoma. Do not use to diagnose diabetes mellitus.
182.
Ordering Recommendation:   Aids in the detection of insulinoma. Do not use to diagnose diabetes mellitus.
183.
Ordering Recommendation:   Screening for anterior pituitary tumor.
184.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
185.
Ordering Recommendation:   Use this test for patients with prolactin-secreting macroadenomas, where a high-dose hook effect is a consideration.
186.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
187.
Ordering Recommendation:   Monitor patient adherence.
188.
189.
190.
191.
Ordering Recommendation:   Assess the risk of distant recurrence in post-menopausal women with early stage (stage I or stage II), hormone receptor-positive (ER+ and/or PR+) breast cancer. Useful in both node-negative and node-positive (1-3 nodes) disease.
192.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
193.
194.
Ordering Recommendation:   Do not use for initial prostate cancer screening; preferred test is total prostate specific antigen (PSA) (0070121) in conjunction with digital rectal exam (DRE). May be useful in distinguishing benign conditions from cancer in patients with mildly elevated total PSA and negative DRE.
195.
Ordering Recommendation:   Preferred initial screening test for prostate cancer in conjunction with digital rectal exam. May use to monitor patients for recurrence of cancer.
196.
Ordering Recommendation:   Preferred initial screening test for prostate cancer in conjunction with digital rectal exam. May use to monitor patients for recurrence of cancer.
197.
Ordering Recommendation:   Do not use for initial prostate cancer screening; preferred test is total prostate specific (PSA) antigen (0070121) in conjunction with digital rectal exam (DRE). May be useful in distinguishing cancer from benign conditions in patients with mildly elevated total PSA and negative DRE.
198.
Ordering Recommendation:   Do not use for initial prostate cancer screening; preferred test is total prostate specific antigen (0070121) in conjunction with digital rectal exam. May be used to monitor disease after radical prostatectomy.
199.
Ordering Recommendation:   Obsolete test for prostate cancer screening; preferred test is total prostate specific antigen (0070121) in conjunction with digital rectal exam.
200.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
201.
Ordering Recommendation:   Acceptable panel to detect protein C and S deficiencies. Preferred test for detecting protein S deficiency is Protein S Free, Antigen (0098894). Do not order if the individual has been on warfarin therapy in the previous 2-4 weeks.
202.
Ordering Recommendation:   Not recommended. Preferred tests for detection of protein C and S deficiencies are Protein C Functional (0030113) and Protein S Free Antigen (0098894). Do not order if individual has been on warfarin therapy in the previous 2-4 weeks.
203.
Ordering Recommendation:   Recommended test to detect protein C deficiency. Do not order if individual has been on warfarin in the previous 2-4 weeks.
204.
Ordering Recommendation:   Acceptable panel to detect and subtype protein C and S deficiencies. Do not order if the individual has been on warfarin therapy in the previous 2-4 weeks.
205.
Ordering Recommendation:   Acceptable test to detect and subtype protein C deficiency. Do not order if individual has been on warfarin therapy in the previous 2-4 weeks.
206.
Ordering Recommendation:   Not recommended for detecting protein C deficiency; preferred test is Protein C, Functional (0030113). Use to subtype deficiency in known protein C-deficient individuals. Do not order if individual has been on warfarin therapy in the previous 2-4 weeks.
207.
Ordering Recommendation:   Aids in the diagnosis and management of multiple myeloma and related disorders when clinical pretest probability is low. Use to detect and quantify monoclonal serum protein.
208.
209.
Ordering Recommendation:   Detects and quantifies monoclonal protein (M-protein) in serum. Use in screening and monitoring of multiple myeloma and related disorders.
210.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
211.
Ordering Recommendation:   Recommended test to detect protein S deficiency. Do not order if individual has been on warfarin therapy in the previous 2-4 weeks.
212.
Ordering Recommendation:   Use to detect and subtype protein S deficiency. Do not order if individual has been on warfarin therapy in the previous 2-4 weeks.
213.
Ordering Recommendation:   Acceptable test for detecting protein S deficiency. Preferred test is Protein S Free, Antigen (0098894). Do not order if the individual has been on warfarin therapy in the previous 2-4 weeks.
214.
Ordering Recommendation:   Not recommended for detecting protein S deficiency; preferred test is Protein S Free, Antigen (0098894). Use to subtype deficiency in known protein S-deficient individuals in combination with Protein S Free, Antigen (0098894), or Protein S, Functional (0030114). Do not order if individual has been on warfarin therapy in the previous 2-4 weeks.
215.
216.
217.
218.
219.
Ordering Recommendation:   Order to detect prothrombin G20210A mutation.
220.
Ordering Recommendation:   Preferred second-line testing for strong suspicion of seronegative antiphospholipid syndrome (APS). Order incrementally or concurrently with other non-criteria antiphospholipid antibody tests.
221.
Ordering Recommendation:   Preferred second-line testing for strong suspicion of seronegative antiphospholipid syndrome (APS). Order incrementally or concurrently with other non-criteria antiphospholipid antibody tests.
222.
Ordering Recommendation:   Preferred second-line testing for strong suspicion of seronegative antiphospholipid syndrome (APS). Order incrementally or concurrently with other non-criteria antiphospholipid antibody tests.
223.
Ordering Recommendation:   Initial test for suspected bleeding or clotting disorder.
224.
225.
226.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
227.
Ordering Recommendation:   Order to detect increased sensitivity in individuals who experience prolonged paralysis following succinylcholine or mivacurium administration.
228.
Ordering Recommendation:   Acceptable test for determining acute exposure to organophosphate insecticides. Preferred test is Insecticide Exposure Panel (0020175).
229.
230.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
231.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
232.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
233.
Ordering Recommendation:   Diagnostic testing for PTEN-related disorders. Predictive testing for PTEN-related disorders.
234.
Ordering Recommendation:   Diagnostic testing for PTEN-related disorders. Predictive testing for PTEN-related disorders.
235.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
236.
Ordering Recommendation:   Alternate test for individuals with clinical symptoms of PAH. Large deletions/duplications will not be detected.
237.
Ordering Recommendation:   Acceptable test for individuals with clinical symptoms of PAH.
238.
Ordering Recommendation:   Preferred test to confirm diagnosis of pulmonary arterial hypertension (PAH), especially in those with known family history.
239.
Ordering Recommendation:   Acceptable panel for individuals with clinical symptoms of pulmonary arterial hypertension (PAH); however, large deletions and duplications will not be detected.
240.
241.
242.
243.
244.
Ordering Recommendation:   An isolated pyruvic acid concentration has little clinical value. Preferred test is Lactate to Pyruvate Ratio, Whole Blood (2007935), which reports concentrations for lactate, pyruvate, and L:P ratio on the same specimen.
245.